Industry News

Global Chemiluminescence Immunoassay (CLIA) Analyzers Market to Surpass USD 7.5 Billion by 2025

By Labmedica International staff writers
30 Nov 2021


The global chemiluminescence immunoassay (CLIA) analyzers market is estimated to grow at a CAGR of 6.4% in the forecast period of 2020-2025 to reach USD 7.6 billion by 2025, with the reagents segment anticipated to capture almost three-fourth of the overall CLIA analyzers market and reach USD 5.7 billion by the end of 2025. The COVID-19 pandemic is anticipated to provide further impetus to the global CLIA analyzers market. Several market players and healthcare agencies are investing in developing COVID-19 diagnostic tests based on the CLIA technique.

These are the latest findings of Fact.MR (Rockville, MD, USA), a market research and competitive intelligence provider.

Infectious disease, autoimmune disease, cardiovascular disease, diabetes, obesity, and cancer are among the chronic disorders for which CLIA solutions are commonly used. They are also used for therapeutic medication monitoring by a number of pharmaceutical corporations and research institutes. Rising awareness of early identification of chronic diseases, and increased medication discovery and development activity by pharmaceutical companies are the key growth drivers of the global CLIA analyzers market. Additionally, rising demand for faster and specific diagnosis to support rapid decision-making is boosting the demand for multiplexed and automated CLIA analyzers. Moreover, the leading players in the CLIA analyzers market have invested heavily in designing several CLIA techniques. This is expected to help them find potential growth inhibiting techniques to contain the spread of COVID-19.

Semi-automated analyzers are anticipated to expand at a healthy CAGR of 6.4% during the forecast period, driven by an uptick in the number of market players offering integrated systems and the prevalence of multiplexed analyzers. By application, the endocrine disorders segment promises impressive growth, mainly due to continuous innovations in test offerings and wide production portfolios of key manufacturers. The endocrine disorders segment is projected to capture almost half the share of the global CLIA analyzers market and register a CAGR of 6.9% during the forecast period. By end-use, the clinical laboratories segment is projected to register a relatively higher CAGR of 6.6% due to rising penetration of private laboratories and growing preference among patients for clinical laboratories. Moreover, the expanding base of clinical laboratories and increase in number of test procedures are likely to drive the growth of the clinical laboratories segment.

Geographically, North America is expected to continue dominating the global CLIA analyzers market, owing to burgeoning demand for faster and specific diagnosis to aid decision-making among end-users. North America is expected to capture nearly two-fifth share of the global CLIA analyzers market and register a CAGR of 6.1% during the forecast period. The Asia-Pacific market for CLIA analyzers has lucrative growth prospects due to the gradual adoption of novel products incorporating CLIA technologies, intensifying market competition among the key players and greater accreditations to establish more laboratories. Asia-Pacific is anticipated to capture a quarter of the global CLIA analyzers market.

Related Links:

E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

21 Jan 2022
Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases
The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application of immunofluorescence assays in clinical diagnostics and research, and growing investments and expenditure in healthcare sector.
Read More
21 Jan 2022
Global Digital X-Ray Systems Market to Be Driven by AI-Based Systems and Robotic Devices
The global digital X-ray systems market was valued at USD 11.74 billion in 2020 and is expected to grow at a CAGR of 7.45% during the forecast period 2021 to 2026, due to the rising number of cancer patients and increasing cases of orthopedic diseases/tumors, cardiovascular diseases (CVD), pneumonia, and dental disorders, among others.
Read More
20 Jan 2022
Illumina and Boehringer Ingelheim Partner to Develop Companion Diagnostics (CDx) for Cancer Treatment
Illumina Inc. (San Diego, CA, USA) has entered into a partnership with Boehringer Ingelheim (Ingelheim am Rhein, Germany; to develop companion diagnostics (CDx) for several programs in the latter’s oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
Read More
20 Jan 2022
Thermo Fisher and Oncocyte to Jointly Develop IVD Test Kits and Companion Diagnostic Tests in Precision Oncology
Oncocyte Corporation (Irvine, CA, USA) has entered into a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s (Waltham, MA, USA) Ion Torrent Genexus System. The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System.
Read More
18 Jan 2022
Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots
The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.
Read More
17 Jan 2022
Mobile C-Arms Market to Surpass USD 1.6 Billion in 2027 Due to Growing Preference for Minimally Invasive Surgeries
The global mobile C-arms market is expected to grow at a CAGR of 5.2% from USD 1.07 billion in 2019 to USD 1.61 billion in 2027, driven primarily by an increase in the global geriatric population, rising burden of chronic and acute diseases across the world, increasing volumes of orthopedic, cardiac, neurological, and oncological surgical procedures, and growing preference for minimally invasive surgeries.
Read More
14 Jan 2022
Medlab Middle East to Reveal Latest Innovations and Technologies in Mobile Labs for COVID-19 Testing
The latest technology and innovation in the global fight against COVID-19 and beyond will be on show at the next edition of Medlab Middle East when it returns to the Dubai World Trade Center from 24-27 January 2022 with mobile molecular testing and diagnosis stations, or ‘laboratories on wheels’, from companies such as Seegene, Inc. (Seoul, Korea) taking center stage.
Read More
13 Jan 2022
Global Coagulometers Market to Be Driven by Rising Prevalence of Blood Disorders
The global coagulometers market is being driven by a rise in the incidence and prevalence of blood disorders such as hemophilia that is fueling the demand for more diagnostic tools.
Read More
11 Jan 2022
Medlab Middle East to Return as Standalone Event in 2023
Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.
Read More
Copyright © 2000-2022 All rights reserved. | Terms And Conditions